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Guanfacine extended-release (GXR), a selective α2A-adrenergic agonist, is a non-stimulant
treatment for attention-deﬁcit/hyperactivity disorder (ADHD). This study assessed the efﬁcacy
(symptoms and function) and safety of dose-optimized GXR compared with placebo in children
and adolescents with ADHD. An atomoxetine (ATX) arm was included to provide reference data
against placebo. Patients (6–17 years) were randomized at baseline to dose-optimized GXR
(0.05–0.12 mg/kg/day – 6–12 years: 1–4 mg/day; 13–17 years: 1–7 mg/day), ATX (10–100 mg/day)
or placebo for 4 or 7 weeks. The primary efﬁcacy measure was change from baseline in ADHD
Rating Scale version IV (ADHD-RS-IV). Key secondary measures were Clinical Global Impression-
Improvement (CGI-I) and the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P;
learning and school, and family domains). Safety assessments included treatment-emergento.2014.09.014
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365903; fax: +34 93 7887641.
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A. Hervas et al.1862adverse events (TEAEs), electrocardiograms and vital signs. A total of 272 (80.5%) patients from
Europe, the USA and Canada completed the study. Signiﬁcant differences were observed in least
squares mean change from baseline in ADHD-RS-IV total score (placebo-adjusted differences)
(GXR: [8.9, po0.001]; ATX: [3.8, po0.05]), the difference from placebo in the percentage
of patients showing improvement (1 [‘very much improved’] or 2 [‘much improved’]) for CGI-I
(GXR: [23.7, po0.001]; ATX: [12.1, po0.05]), WFIRS-P learning and school domain (GXR:
[0.22, po0.01]; ATX: [0.16, po0.05]) and WFIRS-P family domain (GXR: [0.21, po0.01];
ATX: [0.09, p=0.242]). Most common TEAEs for GXR were somnolence, headache and fatigue;
70.1% of GXR subjects reported mild-to-moderate TEAEs. GXR was effective and well tolerated
in children and adolescents with ADHD.
& 2014 Elsevier B.V. and ECNP. Open access under CC BY-NC-ND license.1. Introduction
Attention-deﬁcit/hyperactivity disorder (ADHD) is one of
the most common neurodevelopmental disorders of child-
hood. The worldwide prevalence in children r18 years has
been estimated at 5.3% in a systematic review of 102 studies
from all continents, with a majority from North America and
Europe (Polanczyk et al., 2007).
Stimulant medications, such as methylphenidate and
amphetamine-based medications, have been the mainstay
of pharmacological management for behavioral problems
in children since 1937 (Bradley, 1937). Despite their
effectiveness in treating ADHD, potential issues may arise
in some patients prescribed with stimulant medications,
including side effects and/or inadequate response
(Barkley et al., 1990; Childress and Sallee, 2014; Olfson,
2004). Caution in prescribing stimulants may be required
as pre-existing conditions (such as psychosis, bipolar
disorder, tics, aggressive behavior and certain cardiac
abnormalities) may be exacerbated in some patients
(Cortese et al., 2013; Graham et al., 2011; Wolraich
et al., 2011).
Non-stimulant medications such as guanfacine (extended
release; GXR) and atomoxetine (ATX) are considered as alter-
native options to stimulants for some patients with ADHD
(Biederman et al., 2008a,b; Chappell et al., 1995; Hirota
et al., 2014; Sallee et al., 2009b; Scahill et al., 2001; Silver,
1999; Spencer et al., 2009; Uhlen and Wikberg, 1991; Uhlen
et al., 1995). ATX, a selective norepinephrine reuptake inhi-
bitor, is approved for the treatment of ADHD in children,
adolescents and adults in Europe, the USA and Canada (EMC,
2013). However, through its speciﬁc mechanism of action, it has
shown several of the same side effects as stimulants, such as
increased heart rate and blood pressure (Bushe and Savill,
2014), and up to 12 weeks of treatment can be necessary
before a full response is demonstrated (Bangs et al., 2008;
Bushe and Savill, 2014). Although the precise underlying
physiological mechanisms of GXR are unknown, the beneﬁcial
behavioral effect of GXR on pre-frontal cortex cognitive func-
tions has been well documented (Malhotra et al., 2006; Schulz
et al., 2013; Singh-Curry et al., 2011; Wang et al., 2007).
Efﬁcacy and safety of GXR in patients with ADHD are well
established (Biederman et al., 2008b; Connor et al., 2010;
Kollins et al., 2011; Newcorn et al., 2013; Sallee et al., 2009b).
Two US clinical trials have reported GXR monotherapy to beefﬁcacious and well tolerated (majority of adverse events were
mild to moderate) for the treatment of ADHD (Biederman
et al., 2008b; Sallee et al., 2009b). GXR is currently approved in
the USA as monotherapy or adjunctive treatment in children
and adolescents (6–17 years) with ADHD and in Canada in
children (6–12 years) with ADHD (Health Canada, 2014; Shire,
2014).
The present Phase III trial assessed the efﬁcacy (symp-
toms and function) and safety of once-daily dose-optimized
GXR compared with placebo in the treatment of children
and adolescents aged 6–17 years with a diagnosis of ADHD as
measured by the ADHD Rating Scale version IV (ADHD-RS-IV)
in Europe, the USA and Canada. An ATX arm was included in
the study to provide reference data against placebo.
2. Experimental procedures
A randomized, double-blind, multicenter, parallel-group, placebo-
controlled, dose optimization, efﬁcacy and safety study
(ClinicalTrials.gov identiﬁer: NCT01244490 and EudraCT: 2010-
018579-12) was conducted in centers in Europe, the USA and
Canada. The study was conducted in 58 centers across 11 European
countries (Austria, France, Germany, Ireland, Italy, Poland, Roma-
nia, Spain, Sweden, the UK and Ukraine), the USA and Canada
between January 2011 and May 2013. The study was performed in
accordance with the current applicable regulations, the Interna-
tional Conference on Harmonisation of Good Clinical Practice, the
principles of the Declaration of Helsinki and local ethical and legal
requirements. The study protocol was approved by an independent
ethics committee/institutional review board and regulatory agency
in each center (as appropriate) before study initiation. Written,
informed consent was obtained from each participant's parent or
legal guardian, and assent was obtained from each participant, as
applicable, before commencing study-related procedures.
2.1. Study population
Male and female children/adolescents (6–17 years old) with a
diagnosis of ADHD of at least moderate severity, as deﬁned by a
baseline ADHD-RS-IV with a total score of 32 or higher and a
minimum Clinical Global Impression-Severity (CGI-S) score of 4,
were enrolled in the study. Those with age-appropriate intellectual
functioning; blood pressure measurements within the 95th percen-
tile for age, sex and height; and the ability to swallow tablets or
capsules were included. Girls of childbearing potential had to have
a negative urine pregnancy test at screening and baseline and to
comply with any protocol contraceptive requirements. In addition,
participants and their parent/legal guardian had to be willing, able
1863Efﬁcacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deﬁcitand likely to fully comply with the study procedures and restrictions
deﬁned in the protocol. Subjects who took between 80% and 120%
of their total medication were considered to be compliant with the
study protocol. Exclusion criteria included: clinically signiﬁcant
illness, including a clinically signiﬁcant abnormal screening visit;
current, comorbid psychiatric diagnosis (except oppositional deﬁant
disorder [ODD]); history/presence of cardiac abnormalities, cardi-
ovascular or cerebrovascular disease, serious heart rhythm abnorm-
alities, syncope, tachycardia, cardiac conduction problems,
exercise-related cardiac events or clinically signiﬁcant bradycardia;
orthostatic hypotension and/or a known history of hypertension;
seizures; and glaucoma. In addition, those with a family history of
sudden cardiac death, ventricular arrhythmia or QT prolongation, a
patient history of alcohol or substance abuse and those patients
with serious tic disorder, including Tourette's syndrome, were
excluded. In addition, enrollment was managed to ensure that
approximately 25% of those enrolled were adolescents and at least
25% were female. Furthermore, at least 70% of those enrolled were
to come from European centers and the remaining 30% from USA/
Canada.2.2. Study drug administration
The ﬁrst 4 weeks (7 weeks if aged over 13 years) of the study was a
double-blind dose-optimization period, which was followed by a 6-
week double-blind maintenance period, a 2-week double-blind
tapering period and a follow-up visit 1 week after the last dose
(Figure 1). The total study treatment duration after the screening
period was 10 weeks for children (6–12 years) and 13 weeks for
adolescents (13–17 years), in order to allow all subjects to reach an
optimal dose of between 0.05 mg/kg/day and 0.12 mg/kg/day GXR.
Some incremental beneﬁt may be observed at higher doses, but only if
doses are well tolerated. A few patients may respond adequately at
lower doses, but dose optimization is recommended in all cases. In this
study, titration was at the discretion of the physician. Randomization
occurred at baseline (day 0) and eligible participants were rando-
mized, using a 1:1:1 ratio, to GXR, ATX or placebo (automatically,
randomly assigned by the interactive voice response system). Alloca-
tion to treatment was stratiﬁed within age group (6–12 or 13–17 years)
and country. Subjects were instructed to take their assigned medica-
tion once daily, at a similar time, each morning. They were alsoChildren (6–12 years): 10-week
Atomoxetine
Placebo
Screening
(Visit 1)
Baseline (Visit 2)
randomization Dose optimization
(Visits 3–9, but Visits 7–9 for
adolescents only)
3–35 days Children: 4 weeks
Adolescents: 7 weeks
Guanfacine extended release
Adolescents (13–17 years): 13-wee
Figure 1 Sinstructed to administer medication consistently with respect to the
time of eating and type of food (avoiding a high-fat meal). Medication
was dispensed at the baseline visit, at each dose optimization visit,
each maintenance visit and the ﬁrst tapering visit, for the subsequent
dosing period.
GXR was administered as tablets (1, 2, 3 and 4 mg) and ATX as
capsules (10, 18, 25, 40 and 60 mg) in a double-dummy design. For
GXR, one GXR or matching placebo tablet (if optimized to 1–4 mg
dose) or two tablets (if optimized to 5–7 mg) were taken. GXR
dosing in children was initiated at 1 mg/day and increased by 1 mg
increments after a minimum of 1 week to a maximum of 4 mg/day.
GXR dosing in adolescents was initiated at 1 mg/day and increased
by 1 mg increments after a minimum of 1 week to a maximum dose
of 4, 5, 6 or 7 mg/day if between 34.0 and 41.4, 41.5 and 49.4, 49.5
and 58.4, and 58.5 and 91.0 kg, respectively. For ATX, either one
ATX or matching placebo capsule (if optimized to up to 60 mg/day)
or two capsules (if optimized to more than 60 mg) were taken. ATX
dosing was initiated at 0.5 mg/kg/day in children and adolescents
weighing less than 70 kg at baseline and increased to the target of
approximately 1.2 mg/kg/day and, if well tolerated after a mini-
mum of 1 week, to a maximum of 1.4 mg/kg/day. ATX dosing in
children and adolescents weighing 70 kg or more at baseline (Visit
2) was initiated at 40 mg/day. This was increased to 80 mg/day and
then, following 1 week at 80 mg/day, increased again to 100 mg/
day, if required; this was the total permitted maximum daily dose.
ATX was titrated as supported by the prescribing information/
Summary of Product Characteristics European label. Patients on
both ATX and GXR had the same length of time to optimize.
At least a 30% reduction in ADHD-RS-IV total score from baseline and
a Clinical Global Impression-Improvement (CGI-I) rating of 1 (‘very
much improved’) or 2 (‘much improved’), in the absence of safety or
tolerability issues, was considered to be an optimal response. Patients
who did not achieve the above reduction, but still tolerated the
treatment, could be titrated to a higher dose at the investigator's
discretion. If a 30% or more reduction in ADHD-RS-IV total score from
baseline was achieved, and the optimal dose was well tolerated and
potential additional symptom reduction could be achieved, the dose
could be increased to the next dosage strength. If necessary, the dose
could be lowered once at, or prior to, Week 4 for children or Week
7 for adolescents. Following titration to optimal dose, daily morning
doses were continued for an additional 6 weeks. Upon study comple-
tion or early termination, doses were tapered downward over a 2-week double-blind phase
Dose maintenance
(Visits 10–15)
Taper
(Visits 16 and 17)
Visit 15
evaluation
Follow-
up visit
7 days2 weeks6 weeks
k double-blind phase
tudy design.
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investigational drug.
2.3. Assessments
The following measurements were made during visits throughout the
study: investigator-rated ADHD-RS-IV (DuPaul et al., 1998), CGI-I
scales (Guy, 1976), parental/proxy-rated Weiss Functional Impairment
Rating Scale-Parent Report (WFIRS-P) (Weiss et al., 2007) and CGI-S
(Guy, 1976) (reported in the Supplementary data) to evaluate the
symptoms, disease severity, rate of improvement, function and health
status of trial participants, respectively. All measures used last
observation carried forward (LOCF) methodology. The LOCF technique
was applied when data were missing from a particular visit, but
existed before that visit. This technique creates efﬁcacy records for
missing visits by carrying data values from previous visits forward to
the end. One exception was that observations from the baseline visit
were never carried forward into the treatment phase visits.2.4. Efﬁcacy (symptoms and function)
The primary efﬁcacy measure was the change from baseline in the
investigator-rated ADHD-RS-IV score at Visit 15 (Week 10 for
children and Week 13 for adolescents). The key secondary measures
were the CGI-I rating scale (a binary variable; patients with ‘very
much’ and ‘much improved’ ratings were combined into 1 category
[‘improved’] and the remaining ratings combined into a ‘not
improved’ group) at Visit 15 and disease-speciﬁc function, which
was assessed by change from baseline score of the WFIRS-P learning
and school domain at Visit 15 and change from baseline score
of the WFIRS-P family domain at Visit 15. The WFIRS-P
is a parent-reported measure of ADHD-related functional impair-
ment that is designed for both clinical and research use (CADDRA,
2011). The scale has demonstrated sensitivity (Maziade et al., 2009;
Stein et al., 2011) and addresses the domains of daily functioning
that are likely to be impaired in ADHD (Banaschewski et al., 2013;
Eli Lilly and Co, 2007, 2008). It consists of 50 items rated on a 4-
point Likert scale covering six domains: family, learning and school
(learning and behavior), life skills, child's self-concept, social
activities and risky activities. Total and domain scores are calcu-
lated as either sum or mean scores. The scale was completed by a
parent/proxy. Other secondary measures included CGI-S at Visit 15
and WFIRS-P results for total and other domain scores. Details of
prior medications, including behavioral therapy, were also collected
at baseline. Concomitant behavioral therapy was permitted pro-
vided it had been in place for at least 1 month before the baseline
visit, and was stable throughout the study period.
A comparison between GXR and the ATX reference arm was pre-
speciﬁed, and the comparison used the same methodology as the
primary efﬁcacy analyses. These analyses were not controlled for
multiplicity.
Onset of efﬁcacy (ADHD-RS-IV total score) was investigated as an
ad-hoc analysis by looking at each of the visits in turn until the ﬁrst
LOCF statistical difference between GXR and placebo or ATX and
placebo occurred.
2.5. Safety
Safety assessments included recording any treatment-emergent
adverse events (TEAEs; coded using MedDRAs version 12.1 (MedDRA,
2009)), clinical laboratory results, physical examinations, vital signs
and electrocardiograms (ECGs). In addition, brief psychiatric rating
scale for children (BPRS-C) (Hughes et al., 2001; Overall and
Pfefferbaum, 1982) and Columbia-suicide severity rating scale (C-
SSRS) (Posner et al., 2007) assessments were performed to determinepsychiatric symptomatology and if a suicide-related thought or
behavior occurred.
2.6. Statistical analyses
All randomized participants who received at least one dose of
investigational drug were included in the full analysis set (FAS). All
participants who received at least one dose of investigational drug
were also included in the safety population.
The primary efﬁcacy variable was the change from baseline (Visit
2) for the ADHD-RS-IV total score at Visit 15. Approximately 111
randomized patients per group (GXR and placebo) were required to
detect an effect size of at least 0.45 between GXR and placebo at a
minimum 90% power. In addition, an ATX treatment group of 111
participants to provide reference data for an available non-
stimulant therapy was included. Therefore, a total of 333 rando-
mized participants was planned.
The primary efﬁcacy analyses between GXR and placebo were
conducted using an analysis of covariance (ANCOVA) model with the
Type I error for rejecting the primary analyses null hypothesis set at
0.05 (2-sided). The least squares (LS) means and standard errors
(SEs) for the treatment groups, the difference in LS means between
the treatment groups with 95% conﬁdence intervals (CIs) and the
effect size were calculated as the absolute difference in LS means
between the active treatment and placebo, divided by the root
mean square error; the p-Value for difference between treatment
groups was also derived. For the placebo-adjusted calculations, the
LS mean and SE, effect size and p-Value were based on Type III sum
of squares from an ANCOVA model for the change from baseline
(Visit 2/Week 0), including treatment group, age group and country
as ﬁxed effects, and the baseline ADHD-RS-IV total score as a
covariate.
CGI-I was analyzed using a Cochran–Mantel–Haenszel (CMH) test
stratiﬁed by age group and country to examine treatment group
effects at Visit 15.
CGI-S was summarized at all post-baseline visits and analyzed using a
CMH test stratiﬁed by age group and country to examine treatment
group effects at all visits in the maintenance period. The analyses were
repeated with the responses dichotomized into two categories: 1 or 2
(normal/borderline mentally ill) and 3 or greater (mildly mentally ill or
greater).
WFIRS-P key secondary measures, WFIRS-P global score and
ADHD-RS-IV subscale scores were analyzed using a similar ANCOVA
model as described above.
Safety outcomes were assessed for the safety population. The BPRS-
C total and factor scores were summarized, and the change from
baseline to Visit 15 and LOCF was calculated and summarized. A
summary of results from the C-SSRS rating scale overall on-treatment,
describing patients' responses at screening and all study visits, was
collated. A ‘yes’ response was reported for the suicidal ideation
category as either ‘wish to be dead’ or ‘non-speciﬁc active suicidal
thoughts’ or to the suicidal behavior category as ‘non-suicidal self-
injurious behavior’.
3. Results
3.1. Patient disposition and baseline
characteristics
Of 338 randomized patients, 272 (80.5%) completed the
study to Visit 15 and 66 (19.5%) terminated prematurely
(24/115 [20.9%], 23/112 [20.5%] and 19/111 [17.1%] from
the GXR, ATX and placebo groups, respectively) (Figure 2).
The most frequently reported reason for study discontinua-
tion was lack of efﬁcacy in 5/115 (4.3%), 5/112 (4.5%) and
1865Efﬁcacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deﬁcit14/111 (12.6%) patients treated with GXR, ATX and placebo,
respectively. One patient in the GXR group was lost to
follow-up before receiving any treatment, so was excluded
from the FAS and safety populations.
Baseline characteristics were similar across treatment
groups (Table 1). The mean age (standard deviation [SD])
across treatment groups was 10.8 (2.8) years; children and
adolescents comprised 71.8% and 28.2% of patients, respec-
tively (FAS/safety population). The majority of patients had
the combined subtype of ADHD (85.2%) with a mean ADHD-
RS-IV total score of 43.3 at baseline and mean time since
diagnosis of 2.2 years. The use of at least one prior
stimulant medication was reported by approximately 50%
of all patients (GXR: 54 [47.4%]; ATX: 57 [50.9%]; placebo:
56 [50.5%]), and the use of non-stimulant, non-antipsycho-
tic, psychotropic medication was reported by 20.8% of
patients (GXR: 30 [26.3%]; ATX: 22 [19.6%]; placebo: 18
[16.2%]). The distribution of randomized patients by country
are shown in the Supplementary data.
3.2. Optimal dose
Following dose optimization (dispensed at Visit 10), the
mean (SD) optimal doses were 3.6 (1.3) mg for GXR and 42.1
(20.1) mg for ATX. The mean weight-adjusted optimal doses
were 0.09 (0.03) mg/kg for GXR and 1.03 (0.21) mg/kg for
ATX. No protocol violations were reported; total mean
compliance (SD) was 99.2% (2.9).GXR
n=115 (FAS: n=114a)
Completed to:
Visit 15 (Week 10/13):
n=91 (79.1%)
Visit 17 (Week 12/15):
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Terminated (n=24; 20.9%):
Adverse event (n=9; 7.8%)
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aOne patient was randomized to GXR but did not receive any treatment and was excluded fr
ATX, atomoxetine; FAS, full analysis set; GXR, guanfacine extended release.
Figure 2 Patient disposit3.3. Efﬁcacy
3.3.1. Primary endpoint
Mean ADHD-RS-IV total scores at baseline were similar
across treatment groups (GXR: 43.1; ATX: 43.7; placebo:
43.2) (Table 2). The LS mean (SE) change in ADHD-RS-IV
total score from baseline to Visit 15 (Week 10/13) was
greater for GXR (23.9 [1.2]) compared with placebo
(15.0 [1.2]) (Table 2). The placebo-adjusted difference
in LS mean change from baseline in ADHD-RS-IV total score
(95% conﬁdence interval [CI], p-Value; effect size) for GXR
was 8.9 (11.9, 5.8, po0.001; 0.76).
The LS mean (SE) change in ADHD-RS-IV total score from
baseline to Visit 15 (Week 10/13) for ATX was 18.8 (1.2).
The placebo-adjusted difference in LS mean change from
baseline in ADHD-RS-IV total score (95% CI, p-Value; effect
size) for ATX was 3.8 (6.8, 0.7, p=0.017; 0.32).3.3.2. Key secondary endpoints
The proportions (%) of patients showing an improvement
(1 [‘very much improved’] or 2 [‘much improved’]) in CGI-I
at Visit 15 were 67.9% (76/114), 56.3% (63/112) and 44.1%
(49/111) for GXR, ATX and placebo, respectively. Compared
with placebo, the difference in the percentage of patients
showing improvement in CGI-I rating (95% CI, p-Value) was
23.7 (11.1, 36.4, po0.001) for GXR and 12.1 (0.9, 25.1,
p=0.024) for ATX (Figure 3).ened
404
omized
338
TX
S: n=112)
:
eek 10/13):
5%)
eek 12/15):
5%)
eek 13/16):
7%)
20.5%):
=5; 4.5%)
bject (n=9; 8.0%)
 (n=3; 2.7%)
(n=5; 4.5%)
)
Placebo
n=111 (FAS: n=111)
Completed to:
Visit 15 (Week 10/13):
n=92 (82.9%)
Visit 17 (Week 12/15):
n=92 (82.9%)
Visit 18 (Week 13/16):
n=92 (82.9%)
Terminated (n=19; 17.1%):
Adverse event (n=1; 0.9%)
Withdrawal by subject (n=4; 3.6%)
Lost to follow-up (n=0)
Lack of efficacy (n=14; 12.6%)
Other (n=0)
●
●
●
●
●
Failed screening
n=66
om the FAS and the safety population.
●
●
●
ion (all enrolled patients).
Table 1 Patient baseline characteristics and demographics data (safety population/full analysis set).
GXR (n=114) ATX (n=112) Placebo (n=111)
Mean (SD) age, years 10.9 (2.77) 10.5 (2.81) 11.0 (2.76)
Age group, n (%)
6–12 years 81 (71.1) 82 (73.2) 79 (71.2)
13–17 years 33 (28.9) 30 (26.8) 32 (28.8)
Male, n (%) 76 (66.7) 87 (77.7) 86 (77.5)
Mean (SD) BMI, kg/m2 18.79 (3.02) 18.74 (2.95) 18.78 (2.76)
ADHD subtype, n (%)
Predominantly inattentive 15 (13.2) 10 (8.9) 11 (9.9)
Predominantly hyperactive-impulsive 6 (5.3) 3 (2.7) 5 (4.5)
Combined subtype 93 (81.6) 99 (88.4) 95 (85.6)
Mean (SD) time since ADHD diagnosis, years 2.3 (2.67) 2.0 (2.27) 2.1 (2.57)
Mean (SD) baseline ADHD-RS-IV score 43.1 (5.47) 43.7 (5.86) 43.2 (5.60)
Baseline CGI-S, n (%)
Moderately ill 21 (18.4) 23 (20.5) 33 (29.7)
Markedly ill 60 (52.6) 53 (47.3) 49 (44.1)
Severely ill 30 (26.3) 33 (29.5) 27 (24.3)
Among the most extremely ill subjects 3 (2.6) 3 (2.7) 2 (1.8)
Current psychiatric comorbidities, n (%)
None 97 (85.1) 101 (90.2) 96 (86.5)
Diagnosis of ODDa 17 (14.9) 10 (8.9) 14 (12.6)
Other 1 (0.9) 1 (0.9) 1 (0.9)
Oppositional symptoms, n (%)b 60 (53.1)c 68 (61.8)d 60 (54.1)
ADHD, attention-deﬁcit/hyperactivity disorder; ADHD-RS-IV; ADHD Rating Scale version IV; ATX, atomoxetine; BMI, body mass index;
CGI-S, Clinical Global Impression-Severity; GXR, guanfacine extended release; ODD, oppositional deﬁant disorder; and SD, standard
deviation.
aDiagnosis of ODD per psychiatric history case report form comes from the diagnosis of ODD in the current psychiatric comorbidities
section.
bDeﬁned as a Conners' Parent Rating Scales-Revised: Long oppositional subscale score at the baseline visit of Z14 for males and
Z12 for females.
cn=113.
dn=110.
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baseline in WFIRS-P learning and school domain at Visit 15
(95% CI, p-Value; effect size) for GXR was 0.22 (0.36,
0.08, p=0.003; 0.42) and for WFIRS-P family domain at
Visit 15 (95% CI, p-Value; effect size) was 0.21 (0.36,
0.06, p=0.006; 0.38). The corresponding values for ATX
were 0.16 (0.31, 0.02, p=0.026; 0.32) and 0.09
(0.24, 0.06, p=0.242; 0.16), respectively.
3.3.3. Other secondary endpoints
The placebo-adjusted difference in LS mean change from
baseline in the ADHD-RS-IV hyperactivity/impulsivity score
(95% CI, p-Value; effect size) for GXR was 4.8 (6.4,
3.2, po0.001; 0.79) and a similar change was seen for the
inattention subscale score (4.1 [5.8, 2.5, po0.001;
0.66]). The placebo-adjusted difference in LS mean change
from baseline in the ADHD-RS-IV hyperactivity/impulsivity
score (95% CI, p-Value; effect size) for ATX was 2.0 (3.6,
0.4, p=0.014; 0.33) and for the inattention subscale
score was 1.6 (3.3, 0.0, p=0.053; 0.26).
The ADHD-RS-IV total scores summarized across weight-
adjusted dose are presented in Table 2. The placebo-adjusted
difference in LS mean change from baseline in WFIRS-Pglobal score at Visit 15 (95% CI, p-Value; effect size) for GXR
was 0.17 (0.27, 0.06, po0.001; 0.44) and for ATX was
0.10 (0.21, 0.001, p=0.048; 0.28). WFIRS-P for global
scores and all six domains are presented in Figure 4.
Compared with placebo, the difference in the percentage
of patients with normal/borderline CGI-S at Visit 15 (95% CI,
p-Value) for GXR was 12.3% (0.2, 24.3, p=0.04) and 0.7%
(10.8, 12.1, p=0.69) for ATX.
There was a signiﬁcant difference between GXR and ATX
when analyzing the difference in LS mean change from baseline
in ADHD-RS-IV total score at Visit 15 (95% CI, p-Value;
effect size); 5.1 (8.2, 2.0, p=0.001; 0.440) favoring
GXR (secondary analyses, not controlled for multiplicity).3.3.4. Ad-hoc analyses
Assessing each visit in turn, onset of efﬁcacy for GXR was
seen at Visit 3 (Week 1) with a placebo-adjusted difference in
LS mean (95% CI, p-Value; effect size) of 2.6 (4.3, 0.9,
p=0.003; 0.40). There was no signiﬁcant placebo-adjusted
difference in LS mean (95% CI, p-Value; effect size) for ATX
until Visit 5 (Week 3): 2.7 (5.0, 0.4, p=0.024; 0.31).
Table 2 ADHD-RS-IV total scores (A) and ADHD-RS-IV total score by GXR weight-adjusted dose (B) (full analysis set).
A GXR (n=114) ATX (n=112) Placebo (n=111)
Baseline mean (SD) score 43.1 (5.47) 43.7 (5.86) 43.2 (5.60)
Visit 15 LOCF mean (SD) score 19.2 (11.85) 25.0 (12.97) 28.1 (14.13)
Mean (SD) change from baseline to
Visit 15 LOCF
23.9 (12.41) 18.6 (11.91) 15.0 (13.07)
Comparison to placeboa
LS mean 23.9 18.8 15.0
Difference (95% CI) in LS meansb 8.9 (11.9,
5.8)
3.8 (6.8,
0.7)
Effect size 0.76 0.32
p-Value o0.001 0.017c
B GXR (0.01–0.04
mg/kg) n=13
GXR (0.05–0.08
mg/kg) n=40
GXR (0.09–0.12
mg/kg) n=47
GXR (0.13–0.16
mg/kg) n=12
Visit 15 LOCF mean (SD)d score 20.2 (14.49) 19.3 (12.35) 17.9 (9.76) 22.5 (15.08)
Mean (SD) change from baseline to Visit 15
LOCF
23.1 (15.99) 22.3 (12.03) 26.2 (11.24) 21.2 (13.90)
ADHD-RS-IV; Attention-Deﬁcit/Hyperactivity Disorder Rating Scale version IV; ANCOVA, analysis of covariance; ATX, atomoxetine; CI,
conﬁdence interval; GXR, guanfacine extended release; LOCF, last observation carried forward; LS, least squares; and SD, standard
deviation.
aLS mean and standard error, effect size and p-Value are based on Type III sum of squares from an ANCOVA model for the change
from baseline, including treatment group, age group and country as ﬁxed effects, and baseline value as a covariate.
bA negative difference in LS mean indicates a positive effect of the active treatment over placebo.
cNominal p-Value not corrected for multiplicity.
dSubjects not assigned to a weight-adjusted dose at baseline but are included under all GXR treated.
Difference in percentage of patients with improved CGI–I for active treatment compared with placebo.
Based on Cochran–Mantel–Haenszel statistic comparing the respective treatment group with placebo,
with country and age included as stratification factors.
Nominal p-value uncorrected for multiplicity.
CGI–I, Clinical Global Impression–Improvement; CI, confidence interval.
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Figure 3 Analyses of CGI-I (full analysis set).
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3.4.1. Treatment-emergent adverse events
Eighty-eight (77.2%) patients in the GXR, 76 (67.9%) in the
ATX and 73 (65.8%) in the placebo groups experienced
TEAEs during the study (Table 3). The majority of subjects
reported TEAEs of mild or moderate intensity: GXR 33.3%
mild, 36.8% moderate, 7.0% severe; ATX 41.1% mild, 25.0%
moderate, 1.8% severe; placebo 41.4% mild, 21.6%moderate, and 2.7% severe. No deaths occurred during
the study. Some patients experienced TEAEs that led to
discontinuation from the study (GXR: 9 [7.9%]; ATX:
5 [4.5%]; placebo: 1 [0.9%]). The most commonly reported
TEAEs with GXR were somnolence, headache and fatigue,
whereas with ATX they were decreases in appetite,
nausea and fatigue (Table 3). The most common TEAEs
with placebo were headache, fatigue and abdominal pain.
3.4.2. Serious adverse events
The occurrence of serious adverse events (SAEs) was low in
all treatment groups. Overall, three (1.1%) were reported:
one in the placebo group (syncope [considered treatment
related]) and two in the GXR group (syncope [considered
treatment related] and appendicitis [occurred prior to
randomization and not treatment related]).
3.4.3. ECG and vital signs
There were generally no GXR-related, clinically meaningful
changes in ECG and QTc-related parameters. However, mean
changes from baseline were observed in pulse, systolic and
diastolic blood pressures for GXR and ATX. For example, at Visit
15 (Week 10/13), patients receiving GXR demonstrated a mean
decrease from baseline in supine pulse rate, supine systolic
blood pressure and supine diastolic blood pressure (3.3 beats
per minute [bpm], 2.3 mmHg and 2.2 mmHg, respectively)
compared with those receiving ATX (+2.7 bpm, +1.7 mmHg
and +2.6 mmHg, respectively) and placebo (0.2 bpm,
+0.6 mmHg and +1.3 mmHg, respectively). The blood pressure
and pulse observed in this study are consistent with the overall
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Figure 4 Change from baseline to Visit 15 in WFIRS-P domain and subdomain scores (full analysis set) for (A) guanfacine extended
release versus placebo; and (B) atomoxetine versus placebo.
A. Hervas et al.1868safety proﬁle in previous studies of this class of agent. No
patients withdrew from the study as a result of any ECG or
blood pressure abnormality.3.4.4. Other observations related to safety
The change from baseline in the BPRS-C total score at Week
10/13 (mean [SD]) was 8.3 (8.4), 6.5 (9.2) and 5.6
(8.8) for GXR, ATX and placebo, respectively. Overall for
lifetime history, 10 patients had 1 or more ‘yes’ responses onthe C-SSRS (GXR: 5; ATX: 3; placebo: 2) with ‘yes’ responses
to the suicidal ideation category of the C-SSRS of ‘wish to be
dead’ (GXR: 4; ATX: 3; placebo: 2) and 1 patient to ‘non-
speciﬁc active suicidal thoughts’ (ATX: 1) or to the suicidal
behavior category ‘non-suicidal self-injurious behavior’ (GXR:
1). Overall on-treatment, 10 patients had 1 or more ‘yes’
responses on the C-SSRS (GXR: 3; ATX: 5; placebo: 2). A ‘yes’
response was reported for the suicidal ideation category of
the C-SSRS as either ‘wish to be dead’ (GXR: 2; ATX: 3;
placebo: 1) or ‘non-speciﬁc active suicidal thoughts’ (GXR: 1;
Table 3 TEAEsa occurring in Z5% of patients in any treatment group, by treatment group (safety population).
Preferred term GXR (n=114) ATX (n=112) Placebo (n=111)
Patients, %b Number of AEs Patients, %b Number of AEs Patients, %b Number of AEs
Any TEAE 88 (77.2) 509 76 (67.9) 424 73 (65.8) 322
Somnolence 50 (43.9) 94 20 (17.9) 32 16 (14.4) 18
Headache 30 (26.3) 51 22 (19.6) 36 27 (24.3) 46
Fatigue 29 (25.4) 45 24 (21.4) 32 20 (18.0) 22
Abdominal pain 19 (16.7) 29 19 (17.0) 31 20 (18.0) 32
Nausea 18 (15.8) 19 30 (26.8) 54 11 (9.9) 13
Decreased appetite 15 (13.2) 20 31 (27.7) 44 12 (10.8) 23
Dizziness 14 (12.3) 18 17 (15.2) 24 9 (8.1) 9
Insomnia 13 (11.4) 21 8 (7.1) 10 7 (6.3) 7
Increased appetite 12 (10.5) 15 4 (3.6) 4 9 (8.1) 11
Diarrhea 10 (8.8) 16 2 (1.8) 3 15 (13.5) 18
Anxiety 9 (7.9) 16 7 (6.3) 18 8 (7.2) 15
Upper abdominal pain 7 (6.1) 7 2 (1.8) 3 6 (5.4) 6
Pyrexia 7 (6.1) 9 3 (2.7) 4 4 (3.6) 4
Nasopharyngitis 6 (5.3) 7 3 (2.7) 3 6 (5.4) 7
Nervousness 6 (5.3) 7 6 (5.4) 6 6 (5.4) 7
Vomiting 6 (5.3) 8 18 (16.1) 29 8 (7.2) 9
AE, adverse event; ATX, atomoxetine; CI, conﬁdence interval; GXR, guanfacine extended release; TEAE, treatment-emergent
adverse event.
aTEAEs were deﬁned as AEs that started or worsened during the period between the day of a subject's ﬁrst dose of active treatment
and the third day (inclusive) after treatment was stopped.
bThe denominator for percentages was the number of subjects in the safety population of each treatment group.
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suicidal self-injurious behavior’ (GXR: 1; ATX: 2; placebo: 0).
There were no completed suicides reported. For treatment-
emergent C-SSRS data, there were 7 patients who responded
‘yes’ to the suicidal ideation category (GXR: 2; ATX: 3;
placebo: 2).4. Discussion
GXR demonstrated robust efﬁcacy in terms of improvement
of ADHD core symptoms and global functioning in children
and adolescents with ADHD in this placebo controlled, 10–13-
week, Phase III study. There were clinically relevant and
statistically signiﬁcant differences seen in the primary out-
come measure, change from baseline in ADHD-RS-IV total
score with GXR. Furthermore, statistically signiﬁcant differ-
ences were seen for the key secondary variable measures
(CGI-I, WFIRS-P learning and school domains and WFIRS-P
family domain) for GXR when compared with placebo. The
reference arm, ATX, showed treatment effects consistent
with those seen in other studies (Kratochvil et al., 2001;
Michelson et al., 2002; Spencer et al., 2001, 2002).
The majority of participants who received GXR (n=91;
79%) completed the study. GXR was generally well toler-
ated, with most TEAEs mild or moderate in severity; the
TEAEs that led to study discontinuation included somno-
lence, insomnia and fatigue. The three SAEs reported in the
study were one case of appendicitis (prior to randomization)
and two cases of syncope (one with placebo and one with
GXR). Somnolence, headache and fatigue were morefrequently reported in patients treated with GXR than in
those who received ATX, whereas decreased appetite,
nausea and vomiting were reported more frequently in the
ATX group. The most common AEs reported here were
consistent with the known safety proﬁles of GXR
(Biederman et al., 2008a,b; Sallee et al., 2009a, 2009b;
Spencer et al., 2009), ATX (Kratochvil et al., 2001;
Michelson et al., 2002; Spencer et al., 2001, 2002) and in
a recent meta-analysis of monotherapy/add-on to stimulant
therapy in children/adolescents with ADHD (Hirota et al.,
2014). Analyses showed slightly more pronounced mean
changes from baseline in pulse, systolic and diastolic blood
pressures for GXR and ATX than placebo; these changes
were not unexpected for these two active treatments.
There were no clinically meaningful changes on ECG and
QTc related parameters, and BPRS-C and C-SSRS scores were
similar at baseline and endpoint for all three treatment
groups.
Importantly, while this study was not designed to provide a
head-to-head comparison between GXR and ATX, secondary
pre-speciﬁed analyses (not controlled for multiplicity)
favored GXR versus ATX in ADHD-RS-IV score (5.1 [8.2,
2.0], p=0.001; 0.440), where the mean change from
baseline was greater for GXR than ATX. This is consistent
with other ﬁndings in the literature. In a matching-adjusted
indirect comparison (MAIC) analysis of six studies (two GXR,
four ATX), children and adolescents with ADHD who received
GXR (0.09–0.12 mg/kg/day) were compared with those
receiving ATX (1.2 mg/kg/day). In the base case analysis
comprising three of the studies, GXR produced a signiﬁcantly
greater reduction in mean ADHD-RS-IV total and subscale
A. Hervas et al.1870scores from baseline to ﬁnal on-treatment assessment than
ATX (mean 7.0 [SE 2.2]; po0.01) (Sikirica et al., 2013). A
sensitivity analysis comprising all six studies gave similar
results (mean 7.6 [SE 1.4]; po0.01). Another MAIC study of
GXR and ATX treatment in children and adolescents with
ADHD and ODD also showed greater symptom reduction with
GXR than with ATX (Signorovitch et al., 2012).
In this study, the onset of treatment action observed was
more rapid with GXR than ATX. GXR achieved a statistical
separation from placebo at Week 1 (p=0.001) versus Week
3 for ATX (p=0.024), as measured by the ADHD-RS-IV score.
The 4–7-week dose-optimization period was designed for
each medication based on the prescribing information/
Summary of Product Characteristics for each product and
allowed the investigator ﬂexibility to titrate GXR and ATX to
an optimal therapeutic level in the absence of safety/
tolerability issues (EMC, 2013; NIH, 2014). Adverse events
may have limited the ability to titrate ATX to the optimal
dose rapidly, and may have contributed to the longer time
to response relative to GXR. Importantly, the optimized
doses reached in the trial were generally well balanced
between the two treatments and by Week 7, the majority of
patients in both the GXR (79%) and ATX (73%) groups were
receiving the target daily dose referenced in their respec-
tive prescribing information/Summary of Product Charac-
teristics. The additional 6-week maintenance treatment
period in the trial also gave sufﬁcient time for patients to
achieve their fullest potential response at the optimized
dose for both medications.
This randomized, double-blind, placebo-controlled study
enrolled a large number of patients, a quarter of whom
were female, at multiple centers across Europe, the USA
and Canada. Individuals with comorbid conditions such as
post-traumatic stress disorder, bipolar affective disorder
and severe anxiety disorder were excluded from the study,
but it is often the case in ADHD studies that patients
with current uncontrolled psychiatric comoribidities are
excluded from the trial populations (Kratochvil et al.,
2002; Michelson et al., 2002; Spencer et al., 2002). As such,
the trial population may not be a true reﬂection of patients
with ADHD in the real-world setting, but the ﬁndings of the
current study are consistent with ﬁndings from previous GXR
trials (Biederman et al., 2008a,b; Sallee et al., 2009a,b).
While the proportion of patients recording a formal
diagnosis of comorbid ODD in the present trial is not as
high as the 40–60% cited in the literature (Biederman and
Faraone, 2005; Hazell, 2010; Olfson, 2004), the percentage
of patients with a high burden of comorbid oppositional
symptoms (more than 50% in all treatment groups, mea-
sured by the Conners' Parent Rating Scale) suggests that the
data are generalizable to the wider population.
This Phase III study from centers in Europe, the USA and
Canada evaluated the efﬁcacy and safety of a once-daily
optimized dose of GXR in children and adolescents with
moderate-to-severe symptoms of ADHD and concluded that
GXR was more effective than placebo in improving core
symptoms and global functioning in patients with ADHD.
Efﬁcacy was also demonstrated for the reference arm of ATX
compared with placebo. The pattern and incidence of TEAEs
are consistent with known, published proﬁles of both GXR
and ATX. This study demonstrates a positive risk-beneﬁt
proﬁle in the treatment of children and adolescents withADHD with GXR doses of up to 7 mg (0.05–0.12 mg/kg/day)
and suggests that GXR will be a useful addition to the
existing classes of medication effective in ADHD.
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